Witness the transformative potential of AI in revolutionizing healthcare. Learn how AI is accelerating the identification of novel therapeutic targets, optimizing drug candidate selection, and improving patient outcomes. The panelists will also discuss the challenges and opportunities in integrating AI into healthcare systems and drug discovery and ensuring its safe and ethical use.
Don’t miss this opportunity to learn about the future of AI-driven healthcare innovation.
Dr. Abraham C. Stern leads product management for BioNeMo, NVIDIA's platform for artificial intelligence-aided drug discovery, where he oversees the development of AI-based technologies for chemistry and biology.
Dr. Stern holds a Ph.D. in computational chemistry and has 20 years of experience developing computational tools and algorithms for molecular design and discovery, including the development and use of generative models for chemistry.
He has co-authored 25 scientific peer-reviewed publications, which have been cited 1900+ times and featured on the covers of "Journal of Physical Chemistry" and "Physical Chemistry Chemical Physics".